St John's wort greatly decreases the plasma concentrations of oral S-ketamine

Fundamental and Clinical Pharmacology

Volumn 26, Issue 6, 2012, Pages 743-750

  Peltoniemi, Marko A ^a,b   Saari, Teijo I ^a,b   Hagelberg, Nora M ^a,b   Laine, Kari ^a,b   Neuvonen, Pertti J ^c   Olkkola, Klaus T ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP3A; Drug effect; Interaction; S ketamine; St John's wort

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; ESKETAMINE; HYPERICUM PERFORATUM EXTRACT; KETAMINE; NORKETAMINE; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VISUAL ANALOG SCALE;

ADULT; ANALGESICS; ANTIDEPRESSIVE AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; HYPERICUM; KETAMINE; MALE; NEUROPSYCHOLOGICAL TESTS; PLANT PREPARATIONS; PSYCHOMOTOR PERFORMANCE; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84864286962     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00954.x     Document Type: Article

References (59)

1. Mikkelsen S., Ilkjaer S., Brennum J., Borgjerg F.M., Dahl J.B. The effect on naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology (1999) 90 1539-1545.
2. Bennett G.J. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J. Pain SymptomManage. (2000) 1 S2-S6.
3. Eide P.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain (2000) 4 5-15.
4. Parsons C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. (2001) 19 71-78.
5. Chizh B.A., Headley P.M. NMDA antagonists and neuropathic pain- multible drug targets and multiple uses. Curr. Pharm. Des. (2005) 18 2977-2994.
6. Dworkin R.H., O'Connor A.B., Backonja M. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain (2007) 132 237-251.
7. Bell R.F., Eccleston C., Kalso E. Ketamine as an adjuvant to opioids for cancer pain. A qualitative systematic review. J. Pain Symptom Manage. (2003) 26 867-875.
8. Bell R.F., Dahl J.B., Moore R.A., Kalso E. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anesthesiol. Scand. (2005) 49 1405-1428.
9. Bell R.F. Ketamine for chronic non-cancer pain. Pain (2009) 141 210-214.
10. Zeilhofer H.U., Swandulla D., Geisslinger G., Brune K. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur. J. Pharmacol. (1992) 213 155-158.
11. Øye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. (1992) 260 1209-1213.
12. Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider T.W., Zbinden A.M. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br. J. Anaesth. (1996) 77 625-631.
13. White P.F., Schüttler J., Shafer A., Stanski D.R., Horai Y., Trevor A.J. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br. J. Anaesth. (1985) 57 197-203.
14. Kronenberg R.H. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J. Pain Palliat. Care Pharmacother. (2002) 16 27-35.
15. Hocking G., Cousins M.J. Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. (2003) 97 1730-1739.
16. Visser E., Schug S.A. The role of ketamine in pain management. Biomed. Pharmacother. (2006) 7 341-348.
17. Ben-Ari A., Lewis M.C., Davidson E. Chronic administration of ketamine for analgesia. J. Pain Palliat. Care Pharmacother. (2007) 21 7-14.
18. Grant I.S., Nimmo W.S., Clements J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br. J. Anaesth. (1981) 53 805-810.
19. Clements J.A., Nimmo W.S., Grant I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharm. Sci. (1982) 71 539-542.
20. Chong C., Schug S.A., Page-Sharp M., Jenkins B., Ilett K.F. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin. Drug Investig. (2009) 29 317-324.
21. Yanagihara Y., Kariya S., Ohtani M. et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. (2001) 29 887-890.
22. Hijazi Y., Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. (2002) 30 853-858.
23. Ihmsen H., Geisslinger G., Schüttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin. Pharmacol. Ther. (2001) 70 431-438.
24. Rengelshausen J., Banfield M., Riedel K.D. et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. (2005) 78 25-33.
25. Mueller S.C., Majcher-Peszynska J., Uehleke B. et al. The extent of induction of CYP3A by St John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. (2006) 62 29-36.
26. Michna E., Ross E.L., Hynes W.L. et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage. (2004) 28 250-258.
27. Feng N., Vollenweider F.X., Minder E.I., Rentsch K., Grampp T., Vonderschmitt D.J. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. (1995) 17 95-100.
28. Bond A., Lader M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. (1974) 47 211-218.
29. Hannington-Kiff J.G. Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br. Med. J. (1970) 3 32-34.
30. Stone B.M. Pencil and paper tests - sensitivity to psychotropic drugs. Br. J. Clin. Pharmacol. (1984) 18(Suppl 1) 15S-20S.
31. Jones S.F., McQuay H.J., Moore R.A., Hand C.W. Morphine and ibuprofen compared using the cold pressor test. Pain (1998) 34 117-122.
32. Grach M., Massalha W., Pud D., Adler R., Eisenberg E. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br. J. Clin. Pharmacol. (2004) 58 235-242.
33. Geisslinger G., Thomann P., Knoll R., Kamp H.D., Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br. J. Anaesth. (1993) 70 666-671.
34. Hagelberg N.M., Peltoniemi M.A., Saari T.I. et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur. J. Pain (2009) 14 625-629.
35. Eichenberger U., Neff F., Sveticic G. et al. Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth. Analg. (2008) 106 1265-1273.
36. Kiefer R.T., Rohr P., Ploppa A. et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. (2008) 9 1173-1201.
37. Barnes P.M., Powell-Griner E., McFann K., Nahin R.L. Complementary and alternative medicine use among adults: United States, 2002. Adv Data (2004) 343 1-19.
38. Markowitz J.S., Donovan J.L., DeVane C.L. et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA (2003) 290 1500-1504.
39. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falloon J. Indinavir concentrations and St John's wort. Lancet (2000) 355 547-548.
40. Sugimoto K., Ohmori M., Tsuruoka S. et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. (2001) 70 518-524.
41. Johne A., Brockmöller J., Bauer S., Maurer A., Langheinrich M., Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (hypericum perforatum). Clin. Pharmacol. Ther. (1999) 66 338-345.
42. Bauer S., Stormer E., Johne A. et al. Alterations in cyclosporin A pharmacokinetics and and metabolism during treatment with St John's wort in renal transplant patients. Br. J. Clin. Pharmacol. (2003) 55 203-211.
43. Dresser G.K., Schwarz U.I., Wilkinson G.R., Kim R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther. (2003) 73 41-50.
44. Mai I., Bauer S., Perloff E.S. et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin. Pharmacol. Ther. (2004) 76 330-340.
45. Nieminen T.H., Hagelberg N.M., Saari T.I. et al. St John's wort greatly reduces the concentrations of oral oxycodone. Eur. J. Pain (2010) 14 854-859.
46. Burstein A.H., Horton R.L., Dunn T., Alfaro R.M., Piscitelli S.C., Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. (2000) 68 605-612.
47. Arold G., Donath F., Maurer A. et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. (2005) 71 331-337.
48. Dürr D., Stieger B., Kullak-Ublick G.A. et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. (2000) 68 598-604.
49. Moore L.B., Goodwin B., Jones S.A. et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA (2000) 97 7500-7502.
50. Whitten D.L., Myers S.P., Hawrelak J.A., Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol. (2006) 62 512-526.
51. Imai H., Kotegawa T., Tsutsumi K. et al. The recovery time-course of CYP3A after induction by St John's wort administration. Br. J. Clin. Pharmacol. (2008) 65 701-707.
52. Bruyère A., Declèves X., Bouzom F. et al. Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass. Mol. Pharm. (2010) 7 1596-1607.
53. Hennessy M., Kelleher D., Spiers J.P. et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br. J. Clin. Pharmacol. (2002) 53 75-82.
54. Sigtermans M., Dahan A., Mooren R. et al. S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modelling study in healthy volunteers. Anesthesiology (2009) 111 892-903.
55. Ebert B., Mikkelsen S., Thorkildsen C., Borgbjerg F.M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur. J. Pharmacol. (1997) 333 99-104.
56. Holtman J., Crooks P.A., Johnson-Hardy J.K., Hojomat M., Kleven M., Wala E.P. Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol. Biochem. Behav. (2008) 90 675-685.
57. Huge V., Lauchart M., Schelling G., Beyer A., Thieme D., Azad S.C. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur. J. Pain (2010) 14 387-394.
58. Blonk M.I., Koder B.G., van den Bemt P.M., Huygen F.J. Use of oral ketamine in chronic pain management: a review. Eur. J. Pain (2010) 14 466-472.
59. Marsh J., Hager C., Havey T., Sprague S., Bhandari M., Bryant D. Use of alternative medicines by patients with OA that adversely interact with commonly prescribed medications. Clin. Orthop. Relat. Res. (2009) 467 2705-2722.